Johnson & Johnson (NYSE:JNJ) Shares Sold by KG&L Capital Management LLC

view original post

KG&L Capital Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 13.4% during the first quarter, HoldingsChannel reports. The fund owned 27,590 shares of the company’s stock after selling 4,266 shares during the quarter. Johnson & Johnson comprises 2.0% of KG&L Capital Management LLC’s holdings, making the stock its 11th biggest position. KG&L Capital Management LLC’s holdings in Johnson & Johnson were worth $4,890,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth about $26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $34,000. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $38,000. Advocacy Wealth Management Services LLC lifted its holdings in shares of Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $49,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Raymond James upped their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. UBS Group reduced their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $174.52 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The company has a market cap of $459.23 billion, a P/E ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm’s 50 day moving average is $175.95 and its two-hundred day moving average is $174.39.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. Johnson & Johnson’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.48 earnings per share. Analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.